里程碑制药公司（Milestone Pharmaceuticals Inc.）宣布，正式启动一项关键性的III期临床试验，评估其研发的Etripamil鼻喷雾剂在心房颤动伴快速心室率（Afib-Rvr）患者中的疗效与安全性。该试验的核心亮点在于，这款药物专为患者自我给药设计，旨在为这一常见心律失常提供一种全新的、便捷的治疗选择。
据悉，此项研究将招募大量受试者，以严谨的科学方法验证Etripamil在急性发作场景下，能否迅速且有效地控制心室率、缓解症状，从而帮助患者规避频繁就医或急诊干预的负担。作为一款通过鼻黏膜快速吸收的在研药物，Etripamil有望填补现有治疗方案在院外即时管理方面的空白。
里程碑制药管理层强调，这一里程碑式的进展，标志着公司在该适应症领域的开发策略迈入深水区。若试验结果积极，将有望为全球数百万深受Afib-Rvr困扰的患者带来颠覆性的自我管理方案，显著改善其生活质量与疾病预后。目前，该研究的详细设计及入组标准已同步公布。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.